Roivant Sciences Ltd.(ROIV)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Roivant Sciences Ltd. (ROIV) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ROIV at 12.0/100 on a 32-signal composite quality model, placing it at rank #2,890 of 2,960 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Roivant Sciences Ltd. reports quarterly revenue of $1.4M, net income of $-189.8M, free cash flow of $-270.9M. Top institutional holders of ROIV by reported 13-F value include FMR, BlackRock, MORGAN STANLEY, based on the most recent SEC filings. ROIV trades on the Nasdaq exchange and files with the SEC under CIK 1635088. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ROIV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Roivant Sciences Ltd. directly from SEC EDGAR.
AI Quality Score
12.0/100
AI Rank
#2,890
Revenue
$1.4M
Net Income
$-189.8M
Free Cash Flow
$-270.9M
ROIV key financials by period
Roivant Sciences Ltd. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2026
10-K
$8.3M
$-299.8M
—
FY 2025
10-K
$29.1M
$-172.0M
—
FY 2024
10-K
$32.7M
$4.3B
—
FY 2023
10-K
$31.5M
$-1.0B
—
FY 2022
10-K
$55.3M
$-845.3M
—
FY 2021
10-K
$23.8M
$-809.2M
—
Institutions holding ROIV
Institutional investors reporting a position in Roivant Sciences Ltd. on SEC Form 13F.
